Skip to main content

Table 1 Information of clinical trials of TCR-engineered T cells

From: Targeting cancers through TCR-peptide/MHC interactions

AntigenAmino acid sequence of peptideMHC moleculeCancerTCR usedObjective clincial responseToxicityNumber of patientsReferences
MART-1AAGIGILTVHLA-A*0201MelanomaDMF4(human)2/17 (12%)None17103
MART-1AAGIGILTVHLA-A*0201MelanomaDMF5(human)6/20 (30%)On-target toxicity on normal melanocytes (Skin rash (14/20), Uveitis (11/20), Hearing impairment (10/20))20105
MART-1EAAGIGILTVHLA-A*0201Metastatic melanoma1D3HMCys(human)9/13(69%)Mild skin rash (3/13) serious adverse events(2/13) due to cytokine release syndrome13106
gp100KTWGQYWQVHLA-A*0201Melanomagp100-154 (mouse)3/16 (17%)On-target toxicity on normal melanocytes (Skin rash (15/16), Uveitis (4/16), Hearing impairment (5/16))16103
NY-ESO-1SLLMWITQCHLA-A*0201Melanoma1G4-α95:LY(human)5/11 (45%)None11108
  Synovial sarcoma 4/6 (67%) 6 
CEAIMIGVLVGVHLA-A*0201Metastatic colorectal cancerL110F/S112T (mouse)1/3(33%)Severe inflammatory colitis (3/3) due to on-target toxicity in colon3113
MAGE-A3KVAELVHFLHLA-A*0201Metastatic melanomaMAGE-A3 A118T(mouse)5/9 (56%)Central nervous system toxicities (Necrotizing leukoencephalopathy and death (2/9), Parkinson-like symptoms (1/9), Aphasia (1/9)) due to recognition of MAGE-A12 in the brain7114
  Synovial sarcoma   1 
  Esophageal cancer   1 
MAGE-A3EVDPIGHLYHLA-A*01Ulcerated melanomaMAGE-A3a3a (human)NACardiac toxicity and death (2/2) due to cross-recognition of an unrelated epitope from Titin (TTN)1119
  Myeloma   1 
MAGE-A4NYKRCFPVIHLA-A*2402Esophageal cancerMS-bPa(human)0/10 (0%)None10115
NY-ESO-1SLLMWITQCHLA-A*0201Synovial cell sarcoma1G4-α95:LY (human)11/18 (61%)None18116
  Melanoma 11/20 (55%) 20 
NY-ESO-1SLLMWITQCHLA-A*0201Multiple myelomaNY-ESOc259 (human)16/20 (80%)None20117
WT1CMTWNQMNLHLA-A*2402AML and MDSpMS3-WT1-siTCR(human)2/8 (25%)None8118